辰欣药业
(603367)
| 流通市值：70.36亿 | | | 总市值：70.36亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 850,351,441.43 | 3,444,716,683.93 | 2,583,779,625.67 | 1,739,772,668.35 |
| 营业收入 | 850,351,441.43 | 3,444,716,683.93 | 2,583,779,625.67 | 1,739,772,668.35 |
| 二、营业总成本 | 690,429,639.56 | 3,089,204,509.21 | 2,227,109,205.83 | 1,493,369,715.45 |
| 营业成本 | 357,361,545.27 | 1,657,342,971.8 | 1,160,603,856.12 | 762,686,922.36 |
| 税金及附加 | 12,064,153.87 | 45,373,317.4 | 32,999,589.02 | 21,718,986.97 |
| 销售费用 | 196,161,391.41 | 888,219,982.05 | 633,296,522.77 | 442,378,641.95 |
| 管理费用 | 67,949,242.63 | 242,609,231.4 | 197,677,300.96 | 132,659,889.27 |
| 研发费用 | 61,461,848.05 | 285,782,022.86 | 221,070,437.46 | 145,961,598.45 |
| 财务费用 | -4,568,541.67 | -30,123,016.3 | -18,538,500.5 | -12,036,323.55 |
| 其中:利息费用 | 66,593.09 | 1,335,587.2 | 487,599.15 | 644,994.95 |
| 其中:利息收入 | 7,016,259.94 | 32,616,446.52 | 21,186,428.46 | 13,997,902.78 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -13,177,240.08 | 39,679,633.48 | 23,865,910.95 | 20,859,960.15 |
| 加:投资收益 | 28,213,694.75 | 123,468,458.42 | 98,426,982.61 | 34,665,215.33 |
| 资产处置收益 | 87,224.57 | -707,422.32 | 397,951.72 | 419,694.25 |
| 资产减值损失(新) | -28,091,415.05 | -59,132,365.69 | -59,776,787.56 | -44,149,228.19 |
| 信用减值损失(新) | -8,039,431.17 | -10,186,190.21 | -15,614,142.31 | -13,402,505.99 |
| 其他收益 | 5,332,045.7 | 51,247,530.21 | 20,322,204.23 | 11,938,487.17 |
| 四、营业利润 | 144,246,680.59 | 499,881,818.61 | 424,292,539.48 | 256,734,575.62 |
| 加:营业外收入 | 522,380.75 | 2,653,368.86 | 1,835,959.22 | 854,929.51 |
| 减:营业外支出 | 915,018.35 | 6,340,497.34 | 2,818,401.58 | 1,139,332.25 |
| 五、利润总额 | 143,854,042.99 | 496,194,690.13 | 423,310,097.12 | 256,450,172.88 |
| 减:所得税费用 | 11,742,038.42 | 70,575,825.54 | 38,070,040.27 | 25,161,941.17 |
| 六、净利润 | 132,112,004.57 | 425,618,864.59 | 385,240,056.85 | 231,288,231.71 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 132,112,004.57 | 425,618,864.59 | 385,240,056.85 | 231,288,231.71 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 130,745,202.7 | 421,249,413.74 | 382,012,318.51 | 229,150,905.93 |
| 少数股东损益 | 1,366,801.87 | 4,369,450.85 | 3,227,738.34 | 2,137,325.78 |
| 扣除非经常损益后的净利润 | 116,758,563.01 | 256,314,726.16 | 274,040,508.48 | 179,657,826.73 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.29 | 0.93 | 0.84 | 0.51 |
| (二)稀释每股收益 | 0.29 | 0.93 | 0.84 | 0.51 |
| 八、其他综合收益 | 21,033.62 | 58,501.11 | 455,209.39 | 455,209.39 |
| 归属于母公司股东的其他综合收益 | 21,033.62 | 58,501.11 | 455,209.39 | 455,209.39 |
| 九、综合收益总额 | 132,133,038.19 | 425,677,365.7 | 385,695,266.24 | 231,743,441.1 |
| 归属于母公司股东的综合收益总额 | 130,766,236.32 | 421,307,914.85 | 382,467,527.9 | 229,606,115.32 |
| 归属于少数股东的综合收益总额 | 1,366,801.87 | 4,369,450.85 | 3,227,738.34 | 2,137,325.78 |
| 公告日期 | 2026-04-29 | 2026-04-03 | 2025-10-29 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |